CILP2 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer in The Cancer Genome Atlas (TCGA) study

Table 4 Survival analysis was performed by the Kaplan-Meier method

Variables		N	Means for survival time (month)	Survival time (month, 95% CI)		P value
CILP2 expression	Low	304	83.770	74.181	93.359	0.003
	High	305	70.805	61.802	79.807
	Total	609	77.193	70.583	83.803
Gender	Male	329	74.017	64.871	83.163	0.941
	Female	280	80.242	70.918	89.566
	Total	609	77.193	70.583	83.803
Age	≤ 68	324	86.777	77.219	96.334	< 0.0001
	> 68	285	68.173	59.326	77.021
	Total	609	77.193	70.583	83.803
T stage	T1/2	126	97.409	81.150	113.667	0.003
	T3/4	481	74.489	67.519	81.460
	Total	607	77.572	70.950	84.194
N stage	N0	348	88.348	79.810	96.887	< 0.0001
	N1/2/3	257	63.017	53.234	72.799
	Total	605	77.530	70.908	84.152
M stage	M0	450	87.130	79.689	94.571	< 0.0001
	M1	86	37.131	29.468	44.794
	Total	536	78.778	71.809	85.747
Clinical stage	Stage I/II	330	89.089	80.335	97.843	< 0.0001
	Stage III/IV	262	64.632	54.851	74.413
	Total	592	78.325	71.646	85.005

P value < 0.05 was considered statistically significant (in bold). T tumor, N regional lymph node, M metastasis

ISSN: 1477-7819